

TECHNICAL DATA SHEET

FITC Anti-Human HLA-DR (L243)

Catalog Number: 35-9952

PRODUCT INFORMATION

Contents: FITC Anti-Human HLA-DR (L243)

Isotype: Mouse IgG2a, kappa

Concentration: 5 µL (0.25 µg)/test


Clone: L243

Reactivity: Human

Use By: 12 months from date of receipt

Storage Conditions: 2-8°C protected from light

Formulation: 10 mM NaH₂PO₄, 150 mM NaCl, 0.09% NaN₃, 0.1% gelatin, pH7.2



Human peripheral blood lymphocytes were stained with 5 uL (0.25 ug) FITC Anti-Human HLA-DR (35-9952) (solid line) or 0.25 ug FITC Mouse IgG2a isotype control (dashed line).

DESCRIPTION

The L243 antibody reacts with a member of the human MHC Class II antigens, HLA-DR. The HLA-DR antigen is expressed on B lymphocytes, activated T lymphocytes, activated NK cells, monocytes, macrophages, other antigen presenting cells and progenitor cells. The L243 antibody is specific to an epitope on the alpha subunit of the heterodimeric HLA-DR protein and binds a different epitope than the LN3 antibody clone. It does not cross-react with HLA-DP or HLA-DQ. This antibody is reported to be cross-reactive with non-human primates including Chimpanzee, Cynomolgus, Rhesus and Baboon. Please choose the appropriate format for each application.

PREPARATION & STORAGE

This monoclonal antibody was purified from tissue culture supernatant via affinity chromatography. The purified antibody was conjugated under optimal conditions, with unreacted dye removed from the preparation. It is recommended to store the product undiluted at 4°C, and protected from prolonged exposure to light. Do not freeze.

APPLICATION NOTES

This antibody preparation has been pre-titrated and quality-tested for flow cytometry using an appropriate cell type. The antibody has been diluted for use at 5 µL per test, defined as the amount of antibody that will stain a cell sample in a final volume of approximately 100 µL. The number of cells within a sample should be determined empirically, but typically ranges between 1x10e5 to 1x10e8 cells.

REFERENCES

Brodsky FM. 1984. Immunogenetics. 19(3): 179-194.
 Robbins PA, Evans EL, Ding AH, Warner NL and Brodsky FM. 1987. Human Immunol. 18(4): 301-313.
 Poulin LF, Reyat Y, Uronen-Hansson H, Schraml BU, Sancho D, Murphy KM, Hakansson UK, Moita LF, Agace WW, Bonnet D and Reis e Sousa C. 2012. Blood. 119(25): 6052-6062. (Flow cytometry)
 Shio MT, Hassan GS, Shah WA, Nadiri A, El Fakhry Y, Li H and Mourad W. 2014. J Immunol. 192(6): 2543-2550. (Flow cytometry)
 Bigley V, McGovern N, Milne P, Dickinson R, Pagan S, Cookson S, Haniffa M and Collin M. 2015. J Leukoc Biol. 97(4): 627-634. (Flow cytometry)
 Goodier MR and Londei M. 2000. J Immunol. 165(1): 139-147. (Depletion)
 Kalka-Moll WM, Tzianabos AO, Bryant PW, Niemeyer M, Ploegh HL and Kasper DL. 2002. J Immunol. 169(11): 6149-6153. (Blocking)

Tonbo Biosciences tests all antibodies by flow cytometry. Citations are provided as a resource for additional applications that have not been validated by Tonbo Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.

Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Tonbo Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Tonbo Biosciences, Tonbo Biosciences Logo and all other trademarks are the property of Tonbo Biotechnologies Corporation. © 2013 Tonbo Biosciences.